Lv42
522 积分 2024-01-16 加入
[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
11天前
已完结
54P: Efficacy and safety of firmonertinib 160 mg combined with intrathecal injection pemetrexed in NSCLC patients with EGFR mutations and leptomeningeal metastases
13天前
已关闭
101TiP The efficacy and safety of furmonertinib in advanced NSCLC patients with EGFR mutations and CNS metastases based on ctDNA detection in peripheral blood and CSF (FAITH)
13天前
已关闭
Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
14天前
已完结
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
19天前
已完结
Salvage gemcitabine–vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
21天前
已完结
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
21天前
已完结
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
24天前
已完结
Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study
1个月前
已完结
Cancer Research Communications
1个月前
已完结
皖公网安备34019202002308
